Skip to content
Constant Therapeutics

News & Events

Results: 11

Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa (EB)

Constant Pharmaceuticals today announced that it plans to begin a development program for its compound, TXA127, for the treatment of the rare pediatric disease, epidermolysis bullosa in collaboration with four EB focused charities – DEBRA (Austria), Cure-EB, the Epidermolysis Bullosa Research Partnership (EBRP), and the Epidermolysis Bullosa Medical Research Foundation (EBMRF).… Read more »

Tarix Orphan Receives Rare Pediatric Disease Designation for TXA127 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Cambridge, MA (January 18, 2017): Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted a Rare Pediatric Disease (RPD) designation for the company’s drug candidate TXA127 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. There are currently no approved therapies for RDEB and treatment […]

Tarix Orphan Granted Orphan Drug Status for TXA127 as Potential Treatment for Congenital Muscular Dystrophy (MDC1A)

Cambridge, MA (February 17, 2016): Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted Orphan Drug status to the company’s lead compound, TXA127, for the treatment of laminin-­‐deficient congenital muscular dystrophy (LAMA2 MD or MDC1A). Early-­‐onset LAMA2-­‐related muscular dystrophy occurs in approximately 1 in 30,000 individuals and accounts for between […]

Tarix Orphan, LLC Announces Patent Issuance for TXA127 in Treatment of Marfan Syndrome

TXA127 Shows Positive Activity in Fibrilin Model of Marfan Syndrome Cambridge, MA (August 18, 2015): Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering the use of TXA127 in […]

Tarix Orphan, LLC Announces Positive Results with TXA127 in Animal Model of Congenital Muscular Dystrophy

Results Warrant Further Research into TXA127 as a Comprehensive Single Agent Therapeutic for this Genetic Muscle Disease Cambridge, MA (August 3, 2015): Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the company’s lead compound, TXA127, has shown positive results in […]

Tarix Orphan, LLC Announces Positive Results with TXA127 in Animal Model of ALS

Noted ALS Researcher, Robert H. Brown, Jr., Ph.D., M.D., Joins Tarix Orphan Strategic Advisory Board Cambridge, MA (July 13, 2015): Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the company’s lead compound, TXA127, has shown positive results in the preclinical […]